<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01891357</url>
  </required_header>
  <id_info>
    <org_study_id>WSG-AM07 (Neo-PREDICT-HER2)</org_study_id>
    <secondary_id>2012-003679-21</secondary_id>
    <nct_id>NCT01891357</nct_id>
  </id_info>
  <brief_title>Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer</brief_title>
  <official_title>A Multicenter Site, Open Label, Phase II Trial to Validate Predictive Markers for the Response Evaluation of a Combined Chemo-immunotherapy in Patients With HER2-positive Early Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West German Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>West German Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Neo-PREDICT-HER2 Study is phase II trial to validate predictive markers for the response
      evaluation of a combined chemo-immunotherapy in patients with HER2-positive early breast
      cancer. The only treatment arm consists of Paclitaxel 80 mg/m2 weekly for 12 weeks with
      lapatinib 750 mg P.O. daily and trastuzumab 2 mg/kg IV (loading dose 4 mg/kg) weekly for 12
      weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trastuzumab (T)-containing neoadjuvant chemotherapy has been reported to increase the
      probability of pathological complete response (pCR) in HER2 positive disease up to 67 %.
      Large trials revealed pCR rates (no remaining invasive and in situ components) of about 30-40
      %, if anthracyclines/taxane based polychemotherapy was applied or about 40-45 % if no
      invasive tumor in the breast and lymph nodes was used as a pCR definition.

      Nevertheless, resistance to trastuzumab remains one of the most important challenges in
      adjuvant and metastatic breast cancer therapy causing poor prognosis with an increased
      incidence of cerebral metastasis and limited therapeutic options after disease progression6.
      An improvement shows the combination of trastuzumab and lapatinib, which has been reported to
      have increased efficacy in in-vitro and in metastatic setting in patients who were mostly
      resistant to both therapies in the previous course of disease. Recent data from the
      neoadjuvant setting (neoALTTO) - on a paclitaxel backbone - showed a significantly higher pCR
      rate after L + T than with either compound separately (47 % vs. 20 % and 27.6 %
      respectively). Several trials are planned to evaluate the combination of both therapies in
      the adjuvant and neoadjuvant setting.

      Clinical response measured by sequential evaluation of different proliferation markers (such
      as Ki-67) following a course of neoadjuvant chemotherapy has been demonstrated to correlate
      significantly with an increased risk of relapse in patients not achieving pathological
      complete response. It is therefore clinically relevant to evaluate such proliferation tools
      for early prediction of combination therapy efficacy (chemotherapy and HER2 targeted
      therapy). So far, it remains unclear which method of proliferation measurement is the optimal
      marker for response evaluation regarding a combined chemo-immunotherapy. However, measurement
      of proliferation and apoptosis genes as well as assessment of changes in Phosphatidylinositol
      3-kinases (PI3K), Protein Kinase B (AKT), Insulin-like Growth Factor (IGF) and stem cell
      signalling after a short course of therapy could provide a unique signature for a dynamic
      response evaluation.

      The planned trial will validate predictive markers and a dynamic model based on the
      sequential evaluation of different proliferation and apoptosis markers. Furthermore it will
      assess the pCR-rate after 12 weeks of therapy. The aim of the study is to define a predictive
      marker for the response evaluation of a combined chemo-immunotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response (pCR)</measure>
    <time_frame>Average of 16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event free survival (EFS)</measure>
    <time_frame>5-year survival</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>5-year survival</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Proliferation and apoptosis genes</measure>
    <time_frame>One week before and after three weeks of treatment</time_frame>
    <description>Proliferation Ki-67, Aurora A Kinase (STK15), survivin, Myb-related protein B (MYBL2),Cyclin B1 and apoptosis genes Bcl2, Epidermal Growth Factor-like 2 (SCUBE2), cleaved caspase C3 will be assessed in the samples from diagnostic and sequential biopsy.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Carcinoma, Ductal, Breast</condition>
  <arm_group>
    <arm_group_label>Paclitaxel + Lapatinib + Trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel 80 mg/m2 weekly for 12 weeks with lapatinib 750 mg P.O. daily and trastuzumab 2 mg/kg IV (loading dose 4 mg/kg) weekly for 12 weeks, biopsy before and after three weeks of study treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsy before and after three weeks of study treatment</intervention_name>
    <description>Core biopsies for histological analyses, to be analysed by the central pathology</description>
    <arm_group_label>Paclitaxel + Lapatinib + Trastuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>Paclitaxel + Lapatinib + Trastuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lapatinib</intervention_name>
    <arm_group_label>Paclitaxel + Lapatinib + Trastuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <arm_group_label>Paclitaxel + Lapatinib + Trastuzumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female patients, age at diagnosis 18 - 75 years

          2. Histological confirmed unilateral primary invasive carcinoma of the breast

          3. Clinical Stage Tumor 1 (cT1) (&gt; 1 cm) - Clinical Stage Tumor 4 (cT4) (if operable,
             inflammatory breast cancer is excluded)

          4. HER2 over-expressing tumor confirmed by: 3+ by Immuno-histochemistry (IHC) and/or
             HER2/neu gene amplification by fluorescence, chromogenic or silver in-situ
             hybridization [Fluorescent In-Situ Hybridization (FISH), Chromogenic In-Situ
             Hybridization (CISH) or Silver In-Situ Hybridization (SISH); &gt; 6 HER2 gene copies per
             nucleus or a FISH, CISH or SISH test ratio (HER2 gene copies to chromosome 17 signals)
             of ≥ 2.0]

          5. Clinically node positive disease or node negative disease

          6. No clinical evidence for distant metastasis (cM0) after conventional staging

          7. Performance Status Eastern Cooperative Oncology Group (ECOG) ≤ 1 or Karnofsky Index
             (KI) ≥ 80%

          8. Baseline Left Ventricular Ejection Fraction (LVEF) &gt; 50% measured by echocardiography

          9. Negative pregnancy test (urine or serum) within 7 days prior to start of induction
             treatment in premenopausal patients

         10. The patient must be accessible for treatment and follow-up

         11. Written informed consent including a written informed consent for shipping of tumor
             block for central pathology review and evaluation prior to the start of any study
             procedures

        Exclusion Criteria:

          1. Known hypersensitivity reaction to the compounds or incorporated substances

          2. Known polyneuropathy grade ≥ 2

          3. Have acute or currently active or requiring anti-viral therapy hepatic or biliary
             disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones,
             stable chronic liver disease per investigator assessment).

          4. Prior malignancy with a disease-free survival of &lt; 10 years, except curatively treated
             basalioma of the skin, pTis of the cervix uteri

          5. Prior or concurrent treatment with cytotoxic agents for any reason after consultation
             with the sponsor

          6. Concurrent treatment with other experimental drugs. Participation in another clinical
             trial with any investigational not marketed drug within 30 days prior to study entry

          7. Male breast cancer

          8. Concurrent pregnancy; patients of childbearing potential must implement a highly
             effective (less than 1% failure rate) non-hormonal contraceptive measures during the
             study treatment

          9. Breast feeding women

         10. Sequential breast cancer

         11. Lack of patient compliance

         12. Inadequate organ function including:

               -  Leucocytes &lt; 3.5 x 109/l

               -  Platelets &lt; 100 x 109/l

               -  Absolute Neutrophil Count (ANC) &lt; 1.5 x 109/l

               -  Hemoglobin &lt; 9 g/dl

               -  Serum Creatinine &gt; 1.5 mg/dl

               -  Serum Bilirubin &gt; 1.1 mg/dl

               -  Alkaline phosphatase &gt; 2.5 x Upper Limit of Normal (ULN)

               -  Aspartate Transaminase (ASAT) and/or Alanine Transaminase (ALAT) &gt; 2.5 ULN

               -  Albumin &lt; 2.5 g/dl

         13. Uncompensated cardiac function

         14. Malabsorption syndrome, disease significantly affecting gastrointestinal function

         15. Concomitant use of Cytochrome P450 3A4 (CYP3A4) inhibitors or inducers
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathias Warm, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Krankenhaus Köln Holweide</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mathias Warm, MD</last_name>
    <phone>+49 221 8907</phone>
    <phone_ext>6707</phone_ext>
    <email>warmm@kliniken-koeln.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinikum Esslingen</name>
      <address>
        <city>Esslingen</city>
        <state>Baden-Württemberg</state>
        <zip>73730</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thorsten Kühn, MD</last_name>
      <phone>+49 711 3103</phone>
      <phone_ext>3051</phone_ext>
    </contact>
    <contact_backup>
      <last_name>Angelika Jursik</last_name>
      <phone>+49 711 3103</phone>
      <phone_ext>3064</phone_ext>
      <email>angelikajursik@gmx.de</email>
    </contact_backup>
    <investigator>
      <last_name>Thorsten Kühn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SLK Kliniken</name>
      <address>
        <city>Heilbronn</city>
        <state>Baden-Württemberg</state>
        <zip>74078</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reinhard Hackenberg, MD</last_name>
      <phone>+49 7131 4934</phone>
      <phone_ext>00</phone_ext>
    </contact>
    <investigator>
      <last_name>Reinhard Hackenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt Höchst</name>
      <address>
        <city>Frankfurt (Main)</city>
        <state>Hessen</state>
        <zip>65929</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volker Möbus, MD</last_name>
      <phone>+49 69 3106</phone>
      <phone_ext>2339</phone_ext>
      <email>volker.moebus@klinikumfrankfurt.de</email>
    </contact>
    <investigator>
      <last_name>Volker Möbus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Niels-Stensen-Kliniken</name>
      <address>
        <city>Georgsmarienhütte</city>
        <state>Niedersachsen</state>
        <zip>49124</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert von der Assen, MD</last_name>
      <phone>+49 541 502</phone>
      <phone_ext>2275</phone_ext>
    </contact>
    <investigator>
      <last_name>Albert von der Assen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Westfalen GmbH - Knappschaftskrankenhaus</name>
      <address>
        <city>Dortmund</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44309</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Skrobol, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Anna Moik</last_name>
      <phone>+49 231 9221</phone>
      <phone_ext>078</phone_ext>
      <email>studienzentrale@klinikum-westfalen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Markus Skrobol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bethesda Krankenhaus, Senologie</name>
      <address>
        <city>Duisburg</city>
        <state>Nordrhein-Westfalen</state>
        <zip>47053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Björn Wieland Lisboa, MD</last_name>
      <phone>+49 203 6008</phone>
      <phone_ext>1270</phone_ext>
      <email>senologie@bethesda.de</email>
    </contact>
    <investigator>
      <last_name>Björn Wieland Lisboa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Barbara-KIinik</name>
      <address>
        <city>Hamm</city>
        <state>Nordrhein-Westfalen</state>
        <zip>59073</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herrmann Wiebringhaus, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Scharnewski Christiane</last_name>
      <phone>+49 2381 68123</phone>
      <phone_ext>52</phone_ext>
      <email>sscharnewski@barbaraklinik.de</email>
    </contact_backup>
    <investigator>
      <last_name>Hermann Wiebringhaus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Köln Holweide, Brustzentrum</name>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51067</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathias Warm, MD</last_name>
      <phone>+49 221 8907</phone>
      <phone_ext>6707</phone_ext>
      <email>warmm@kliniken-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Mathias Warm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz gGmbH</name>
      <address>
        <city>Chemnitz</city>
        <state>Sachsen</state>
        <zip>09116</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikos Fersis, MD</last_name>
      <phone>+49 371 333</phone>
      <phone_ext>22200</phone_ext>
    </contact>
    <investigator>
      <last_name>Nikos Fersis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Praxis für gynäkologische Onkologie am Brustzentrum City</name>
      <address>
        <city>Berlin</city>
        <zip>10713</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lidia Perlova-Griff, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Michaela Platzer</last_name>
      <phone>+49 30 8272</phone>
      <phone_ext>29840</phone_ext>
      <email>michaela.platzer@sankt-gertrauden.de</email>
    </contact_backup>
    <investigator>
      <last_name>Lidia Perlova-Griff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2013</study_first_submitted>
  <study_first_submitted_qc>July 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2013</study_first_posted>
  <last_update_submitted>August 6, 2015</last_update_submitted>
  <last_update_submitted_qc>August 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Unilateral primary invasive carcinoma of the breast</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Ductal</mesh_term>
    <mesh_term>Carcinoma, Ductal, Breast</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

